The prevalence of allergic rhinitis (AR) in the pediatric population is estimated worldwide at 10-20%. The efficacy and safety of bilastine (a second-generation antihistamine) in adult patients and adolescents have already been proven in clinical studies. Below we summarize experiences with its use in children under 12 years of age.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
